Leerink Upgrades Ionis to Outperform, Cites Angelman Drug
Leerink Partners Upgrades Ionis Pharmaceuticals(IONS.US) to Buy Rating, Announces Target Price $62
Ionis Pharmaceuticals Price Target Raised to $68.00/Share From $67.00 by B of A Securities
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $48 to $82
TD Cowen Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)
TD Cowen Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Maintains Target Price $30
Beam Therapeutics Analyst Ratings
H.C. Wainwright Initiates Beam Therapeutics(BEAM.US) With Buy Rating, Announces Target Price $80
Buy Rating on Ionis Pharmaceuticals Backed by Strong Trial Results for Angelman Syndrome Drug
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Lifestance Health Group (LFST) and Agilent (A)
Ionis Pharmaceuticals' ION582 Garners Buy Rating Amidst Promising Efficacy and Safety Data
Ionis Pharmaceuticals Analyst Ratings
Buy Rating Justified by Strong Demand and Strategic Expansion of Twist Bioscience's Express Genes
CareDx Analyst Ratings
Stifel Nicolaus Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)
The Latest Analyst Ratings For Ionis Pharmaceuticals
Ionis Pharmaceuticals Analyst Ratings
Ionis Pharmaceuticals' Promising ION582 Leads to Buy Rating Amidst Angelman Syndrome Treatment Potential
JPMorgan Adjusts Price Target on Nurix Therapeutics to $34 From $31, Maintains Overweight Rating
Nurix Therapeutics Analyst Ratings